From TokenPost · · 50s
Vivos Targets $3.8 Million Revenue Lift
Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027.
In brief
Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract talks by early 2027. Vivos Therapeutics targets $3.8 million in additional annual revenue from payer contract renegotiations to achieve positive operating cash flow by early 2027. Originally reported by TokenPost.
Vivos Therapeutics Revenue Target

Vivos Therapeutics aims to boost annual revenue by $3.8 million through payer contract renegotiations to achieve positive operating cash flow by early 2027.
Financial Risks
Management reported $200,000 in cash and warned of substantial doubt about Vivos’ ability to continue as a going concern.
Nasdaq Listing Risk
Vivos remains out of compliance with Nasdaq’s $1 minimum bid-price requirement, risking delisting if the closing bid stays at or below $0.10 for 10 straight business days.
The headline
Vivos Therapeutics targets $3.8 million in additional annual revenue from payer contract renegotiations to achieve positive operating cash flow by early 2027.
Read the TL;DR — this story on one card.





